PDCD1 and neoplasm: This subset is also thought to exhibit tumor-reactive characteristics, as evidenced by our finding showing a high tumor-reactive score, consistent with 2 previous studies (Fig. 3k; Supplementary Fig. 5f).24,25 These observations suggest that anti-PD-1 blockade elicits both tumor-specific CD8+ and CD4+ T-cell responses.